Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F21%3A10411077" target="_blank" >RIV/00064203:_____/21:10411077 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/21:10411077

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=n7HY7Lm..-" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=n7HY7Lm..-</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41375-020-0841-x" target="_blank" >10.1038/s41375-020-0841-x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents

Popis výsledku v původním jazyce

Data on the spectrum of second malignant neoplasms (SMNs) after primary childhood non-Hodgkin&apos;s lymphoma (NHL) are scarce. One-hundred-and-eighty-nine NHL patients diagnosed in a 30 years period of 1980-2010 developing an SMN were retrieved from 19 members of the European Intergroup for Childhood NHL and/or the international Berlin-Frankfurt-Münster Study Group. Five subgroups of SMNs were identified: (1) myeloid neoplasms (n = 43; 23%), (2) lymphoid neoplasms (n = 51; 27%), (3) carcinomas (n = 48; 25%), (4) central nervous system (CNS) tumors (n = 19; 10%), and (5) &quot;other&quot; SMNs (n = 28; 15%). In 37 patients (20%) preexisting disorders were reported with 90% having any kind of cancer predisposition syndrome (CPS). For the 189 primary NHL patients, 5-year overall survival (OS) after diagnosis of an SMN was 56 +- 4%, being worst for patients with preexisting disorders at 28 +- 8%. Five-year OS rates were 38 +- 8%, 59 +- 7%, 79 +- 8%, 34 +- 12%, and 62 +- 11%, respectively, for patients with myeloid and lymphoid neoplasms, carcinomas, CNS tumors, and &quot;other&quot; SMNs (p &lt; 0.0001). Patients with SMNs after childhood NHL having a reported CPS, mostly mismatch repair disorders, carried a very poor prognosis. Moreover, although outcome was favorable in some subtypes of SMNs after childhood NHL (carcinomas, lymphoid neoplasms), other SMNs such as myeloid neoplasms and CNS tumors had a dismal prognosis.

Název v anglickém jazyce

Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents

Popis výsledku anglicky

Data on the spectrum of second malignant neoplasms (SMNs) after primary childhood non-Hodgkin&apos;s lymphoma (NHL) are scarce. One-hundred-and-eighty-nine NHL patients diagnosed in a 30 years period of 1980-2010 developing an SMN were retrieved from 19 members of the European Intergroup for Childhood NHL and/or the international Berlin-Frankfurt-Münster Study Group. Five subgroups of SMNs were identified: (1) myeloid neoplasms (n = 43; 23%), (2) lymphoid neoplasms (n = 51; 27%), (3) carcinomas (n = 48; 25%), (4) central nervous system (CNS) tumors (n = 19; 10%), and (5) &quot;other&quot; SMNs (n = 28; 15%). In 37 patients (20%) preexisting disorders were reported with 90% having any kind of cancer predisposition syndrome (CPS). For the 189 primary NHL patients, 5-year overall survival (OS) after diagnosis of an SMN was 56 +- 4%, being worst for patients with preexisting disorders at 28 +- 8%. Five-year OS rates were 38 +- 8%, 59 +- 7%, 79 +- 8%, 34 +- 12%, and 62 +- 11%, respectively, for patients with myeloid and lymphoid neoplasms, carcinomas, CNS tumors, and &quot;other&quot; SMNs (p &lt; 0.0001). Patients with SMNs after childhood NHL having a reported CPS, mostly mismatch repair disorders, carried a very poor prognosis. Moreover, although outcome was favorable in some subtypes of SMNs after childhood NHL (carcinomas, lymphoid neoplasms), other SMNs such as myeloid neoplasms and CNS tumors had a dismal prognosis.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia

ISSN

0887-6924

e-ISSN

—

Svazek periodika

35

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

16

Strana od-do

534-549

Kód UT WoS článku

000531783100002

EID výsledku v databázi Scopus

2-s2.0-85084465559